Background: Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.
Methods: In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7).
Results: We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05).
Conclusion: In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.
Keywords: Antiviral intervention; Arbidol; Combination therapy; Corona Virus Disease 2019; Lopinavir/ritonavir.
Copyright © 2020. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interest.
Compounds with therapeutic potential against novel respiratory 2019 coronavirus.Antimicrob Agents Chemother. 2020 Mar 9:AAC.00399-20. doi: 10.1128/AAC.00399-20. Online ahead of print. Antimicrob Agents Chemother. 2020. PMID: 32152082 Review.
Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.J Infect. 2020 Mar 20. doi: 10.1016/j.jinf.2020.03.001. Online ahead of print. J Infect. 2020. PMID: 32171867 Free PMC article.
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25729. Online ahead of print. J Med Virol. 2020. PMID: 32104907 Review.
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.Antivir Ther. 2014;19(6):579-86. doi: 10.3851/IMP2737. Epub 2014 Jan 24. Antivir Ther. 2014. PMID: 24464590 Clinical Trial.
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.Indian J Med Res. 2020 Mar 11. doi: 10.4103/ijmr.IJMR_502_20. Online ahead of print. Indian J Med Res. 2020. PMID: 32202256